Please assess the completion status of the following clinical trial:

Trial Title: Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A. Hospital setting: positive virus test for SARS-CoV-2 using RT-PCR, or positive point-of-care viral infection test in the presence of strong clinical suspicion of SARS-CoV-2 infection.~   B. Home setting: positive virus test for SARS-CoV-2 using a molecular assay e.g. RT-PCR in the presence of strong clinical suspicion of SARS-CoV-2 infection.~2. Male or female, ≥18 years of age (hospital setting) or ≥50 years of age (home setting) at the time of consent.~3. A. Hospital setting: patients admitted to hospital due to the severity of their COVID 19 disease OR~   B. Home setting: non-hospitalised patients from high-risk groups, defined as ≥65-years of age, or ≥50 years of age and with any of the following risk factors:~  * Arterial hypertension~  * Cardiovascular disease~  * Diabetes mellitus~  * Chronic lung disease~  * Chronic kidney disease (eGFR \<60 mL/min/1.73m2)~  * Chronic liver disease~  * Immunodeficiency due to a serious illness or medication~  * Cerebrovascular disease~  * Malignancy (except basal cell carcinoma) diagnosed in the last 5 years~  * Body Mass Index ≥30 who present with clinical symptoms consistent with COVID-19:~  * High temperature and/or~  * New, continuous cough.~  * Loss or change to sense of smell and/or taste~4. Provide informed consent.~5. A. Hospital setting: hospitalised female patients must be ≥1 year post-menopausal, surgically sterile, or using an acceptable method of contraception.~B. Home setting: non-hospitalised female patients must be ≥1 year post-menopausal or surgically sterile.~Exclusion Criteria:~1. \> 24 hours after confirmation of SARS-CoV-2 infection by a molecular assay e.g. RT-PCR test (hospital and home settings) or \>24 hours after a positive point-of-care viral infection test (hospital setting only). This criterion does not apply to patients in the hospital setting who had their positive RT-PCR test for SARS-CoV-2 performed prior to hospitalisation.~2. ≥ 8 days from onset of COVID-19 symptoms (cough and/or fever and/or loss or change to sense of smell and/or taste; home setting only).~3. Any condition, including findings in the patients' medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for the participation of the patient into the study or that could interfere with the study objectives, conduct or evaluation.~4. Current or previous participation in another clinical trial where the patient has received a dose of an Investigational Medicinal Product (IMP) containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.~5. Ventilated or in intensive care.~6. Inability to use a nebuliser with a mouthpiece.~7. History of hypersensitivity to natural or recombinant IFN-β or to any of the excipients in the drug preparation.~8. Females who are breast-feeding, lactating, pregnant or intending to become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SNG001 (Type: ACTIVE_COMPARATOR): inhalation using the I-neb device.
- Placebo (Type: PLACEBO_COMPARATOR): inhalation using the I-neb device.

Based on this trial design, predict the completion outcome and termination type (if applicable).